They mostly present at stage I (tumor is confined to the ovaries) and feature certain mutations, for example K-Ras, B-Raf or PTEN. The tumorigenic pathway in type I carcinomas is characterized by the development through atypically proliferating or borderline tumors which can be considered as an adenoma-carcinoma sequence. Here, BRAF is linked to carcinoma.